Elizabeth Plimack MD

Deputy Director @FoxChaseCancer. Professor GU Med Onc. @ASCO BOD 2020-24. Views mine. COI:

[Elizabeth Plimack MD @ERPlimackMD]

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

[Pauline Funchain @FunchainMD]

Comprehensive talk on distinguishing AEs from IO combos with nonIO agents @MattZibelman @FoxChaseCancer #ASCO26, best to watch this one but main points:
➡️treatment goal matters
➡️timing one of the best methods to distinguish irAE from chemo/TKI/ADC
➡️if in doubt hold and work up

[Elizabeth Plimack MD @ERPlimackMD]

@AmandaNizamMD @GhataliaPooja @FoxChaseCancer @MattZibelman @OncoAlert @scocmem @nataliagandur Thanks Amanda!

[Amanda Nizam, MD @AmandaNizamMD]

Excellent patient-centric trial led by @GhataliaPooja & the excellent team at @FoxChaseCancer @ERPlimackMD @MattZibelman #DanGeynisman @OncoAlert @scocmem @nataliagandur

[Matthew Zibelman @MattZibelman]

@AmandaNizamMD @GhataliaPooja @FoxChaseCancer @ERPlimackMD @OncoAlert @scocmem @nataliagandur Turning EV/P into an induction and maintenance approach. IMPROEV= Induction & Maintenance w PembRO & EV. Goal to IMPROVE outcomes for mUC pts. Switch the last 2 letter for EV ;)

[Petros Grivas @PGrivasMDPhD]

@ERPlimackMD @ASCO #ASCO26 @OncoAlert

[Sneha Singh, MD @SnehaSinghMD]

Join us today to learn more about building your path to leadership with Drs. @DianeReidyLagun @KimrynRathmell @ERPlimackMD
📍 Location : RM S502, Women's Networking Center
⌚ Time : June 1st, 11 AM CT
@ASCO #ASCO2026 @OSUhemoncfellow @DukeFellows @FoxChaseCancer @IMG_Oncologists @hemeoncfellow

[Brian Rini, MD @brian_rini]

Does CTLA-4 inhibition benefit RCC patients?

[Mary Feng @MaryFengMD]

Eric Small’s @ASCOPres Address. Cancer is personal. It affects our families, friends, and neighbors. Translating science to clinics everywhere. #science @ucsfcc

[Chana Weinstock GU Onc MD @chana_weinstock]

Please join us on May 18 for our NMIBC workshop. Honored to be joined by a wonderful lineup of panelists including @UroDocAsh @djmcconkey @garysteinbergmd @h_alahmadie @MaxKates @pjhensley11 @spsutkaMD @pcvblack @FaltasLab @MattGalsky @drdonnahansel @ERPlimackMD @SimaPorten

[Elizabeth Plimack MD @ERPlimackMD]

@uretericbud This AI avatar thing is both hilarious and terrifying!

[Elizabeth Plimack MD @ERPlimackMD]

@Dr_RaviMadan @thenci @melissaabel20 @EdwinPosadasMD @RickLee6 @PCFnews @urotoday @DeborahCitrin @gulleyj1 @billdahutmd @RPachynski @apolo_andrea @PGrivasMDPhD Ravi what a legacy you are leaving at the NCI! Best wishes in your new role!

[Kidney Cancer @KidneyCancer]

ONE MORE DAY! Collaboration is key to finding a cure. 🤝

We're thrilled to partner with the Korek Foundation and @kidneycoa to offer specialized #kidneycancer research grants this year.

Don't miss the opportunity to apply for our 2026 Award Program: https://t.co/NJGM7YS6dz

[Elizabeth Plimack MD @ERPlimackMD]

Circulating biomarkers are coming of age in @kidneycancer - expert overview by @TiansterZhang at #IKCSEU26 @OncoAlert

[Kidney Cancer @KidneyCancer]

🏆 Congratulations to Dr. Samra Turajlic @CRUK_MI on receiving the KCA's Pieter de Mulder award! We're grateful for your excellence in #kidneycancer oncology care and all your contributions to the field. #IKCSEU26

[Elizabeth Plimack MD @ERPlimackMD]

The IKCC patient survey provides us a wealth of information to understand the #kidneycancer patient perspective. Shared decisionmaking is an art, we all have room to improve.

[OncoAlert @OncoAlert]

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
Treatment Barriers and Shared Decision-Making Disparities in Kidney Cancer Across Europe: Results from the IKCC Global Patient Survey Presenter Dr. Eric Jonasch 🇺🇸

The International Kidney Cancer Coalition (IKCC) launched its fourth Global Patient Survey in 2024 and sought input from patients associated with its partner organizations on key topics pertaining to patient knowledge, engagement, and outlook. Globally, 2,677 responses were received, including 1,247 responses from Europe, with input from 1003 patients and 244 carers. Despite higher reported involvement in shared decisionmaking in Europe versus the rest of the world, significant differences are observed between countries, and barriers persist across Europe. There remains an unmet need for enhanced clinician–patient communication, improved patient education, and access to care. Working with patient organizations in a country-specific manner may help decrease disparities.

@KidneyCancer
Jean-Christophe Bernhard @univbordeaux
@AlbigesL @gustaveroussy
@TiansterZhang
@Dr_SabyGeorge
@ZakhariaYousef
@ERPlimackMD
@Ric_Campi
@DrIacovelli
@RebuzziSara
@weoncologists
@GEVaughan1
@salvolarosa
@DrYukselUrun
#KidneyCancer
@daniyal_jafree
@EJonasch
@IKCCorg
@sophiemerrick1
@BarbaraJereczek
@ESTRO_RT
@ZakhariaYousef
@kuraoncology
@Selcuk__Erdem
@drulkav

[Elizabeth Plimack MD @ERPlimackMD]

@KidneyCancer @OncoAlert @weoncologists @ZakhariaYousef @Ric_Campi @DrDanielHeng @Dr_SabyGeorge @DrIacovelli @RebuzziSara @TiansterZhang Happy to be here! Full house on day 2!

[OncoAlert @OncoAlert]

DAY TWO of OncoAlert 🚨 Coverage of #IKCSEU26
Quality of Life and Survivorship with Adjuvant Immunotherapy: Insights From the Patient Experience Presenter Dr. Sophie Merrick 🇬🇧

Adjuvant ICIs are now standard of care in resected RCC, so understanding their impact on quality of life is essential. Many patients tolerate treatment well, but a subset experience chronic irAEs that affect daily life and are not reflected in current PROMs. Patients consistently identified the duration of toxicity as the main driver of burden, influencing confidence, independence and work or financial stability. These insights highlight the need for trial reporting that includes irAE duration and resolution, the use of ICI‑specific PROMs, and integrated survivorship care across oncology, primary care and specialist teams.

@KidneyCancer
Jean-Christophe Bernhard @univbordeaux
@AlbigesL @gustaveroussy
@TiansterZhang
@Dr_SabyGeorge
@ZakhariaYousef
@ERPlimackMD
@Ric_Campi
@DrIacovelli
@RebuzziSara
@weoncologists
@GEVaughan1
@salvolarosa
@DrYukselUrun
#KidneyCancer
@daniyal_jafree
@EJonasch
@IKCCorg
@sophiemerrick1
@BarbaraJereczek
@ESTRO_RT
@ZakhariaYousef
@kuraoncology
@Selcuk__Erdem
@drulkav

[Andrea Necchi, MD, FASCO @AndreaNecchi]

A lot of intense discussions ongoing at @SanRaffaeleMI around biomarkers in GU cancers! @IBCG_BladderCA @GTumors @UroDocAsh @SpiessPhilippe

[Yüksel Ürün @DrYukselUrun]

Early EV dose reduction in advanced urothelial cancer ↘️ treatment interruption risk by half, yet survival stayed the same.
@JAMAOnc @OncoAlert @WorldBladderCan @Uromigos
https://t.co/sbC1ZA95EW

[Laura Esfeller @LauraEsfeller]

Dr. Michael Jewett receives the Dr. Nicholas Vogelzang Humanitarian Award from @KidneyCancer #IKCSNA25 & gives credit to his “patient mentors” including the formidable Deb Maskens. What a gift it was to be Dr. V’s patient. I’m alive AND a patient advocate because of him. 🧡